CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 142 filers reported holding CYMABAY THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.69 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $894,600 | -78.6% | 60,000 | -87.5% | 0.00% | -77.8% |
| Q1 2023 | $4,187,100 | -4.3% | 480,172 | -31.2% | 0.02% | -60.0% |
| Q4 2022 | $4,373,325 | -5.7% | 697,500 | -47.4% | 0.04% | +9.8% |
| Q3 2022 | $4,638,000 | +4.8% | 1,325,000 | -11.7% | 0.04% | +24.2% |
| Q2 2022 | $4,425,000 | +81.3% | 1,499,900 | +91.1% | 0.03% | 0.0% |
| Q1 2022 | $2,441,000 | +11.1% | 785,000 | +20.8% | 0.03% | +50.0% |
| Q4 2021 | $2,197,000 | +58.4% | 650,000 | +71.0% | 0.02% | +15.8% |
| Q3 2021 | $1,387,000 | +6.0% | 380,052 | +26.7% | 0.02% | +18.8% |
| Q2 2021 | $1,308,000 | +40.5% | 300,000 | +46.3% | 0.02% | +45.5% |
| Q1 2021 | $931,000 | -12.5% | 205,000 | +10.5% | 0.01% | +83.3% |
| Q4 2020 | $1,064,000 | -9.0% | 185,518 | -44.6% | 0.01% | -70.0% |
| Q2 2020 | $1,169,000 | +267.6% | 335,000 | +55.8% | 0.02% | +150.0% |
| Q1 2020 | $318,000 | -50.1% | 215,000 | -33.8% | 0.01% | -42.9% |
| Q4 2019 | $637,000 | +537.0% | 325,000 | +2221.4% | 0.01% | +600.0% |
| Q2 2019 | $100,000 | – | 14,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,629,464 | $14,208,926 | 10.61% |
| Lynx1 Capital Management LP | 1,369,927 | $11,945,763 | 9.96% |
| Versant Venture Management, LLC | 543,753 | $4,741,526 | 9.88% |
| Foresite Capital Management IV, LLC | 1,787,094 | $15,583,460 | 8.09% |
| Octagon Capital Advisors LP | 4,570,918 | $39,858,405 | 5.74% |
| ACUTA CAPITAL PARTNERS, LLC | 878,500 | $7,660,520 | 5.64% |
| TCG Crossover Management, LLC | 3,048,257 | $26,580,801 | 5.18% |
| Affinity Asset Advisors, LLC | 1,083,118 | $9,444,789 | 3.12% |
| Altium Capital Management LP | 620,000 | $5,406,400 | 3.00% |
| Bain Capital Life Sciences Investors, LLC | 2,500,000 | $21,800 | 2.72% |